Evidence map›Paper›PMID 21791540›Full record

Trial reportEuropean journal of heart failure2011

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

Alan S Maisel, Christian Mueller, Robert Fitzgerald, Robert Brikhan, Brian C Hiestand, Navaid Iqbal, Paul Clopton, Dirk J van Veldhuisen

Registry-linked trialOpen access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01570153 (Biomarkers Plus Bioimpedance Vector Analysis to Predict Cardiorenal Syndrome Onset and Prognosis in Patients With Acutely Decompensated Heart Failure), which is not on this map. Cited by 101 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 4 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01570153 completednot on this mapstarted 2012, after this paper: background citation

Biomarkers Plus Bioimpedance Vector Analysis to Predict Cardiorenal Syndrome Onset and Prognosis in Patients With Acutely Decompensated Heart Failure: Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial

TypeobservationalSponsorMassachusetts General HospitalRan2012 to 2013Enrolled100ConditionsCardiorenal Syndrome, Acute Decompensated Heart Failure
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Biomarkers of Hemodynamic Congestion in Heart Failure.Current heart failure reports · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Alan S MaiselSan Diego Veterans Affairs Medical Center, 3350 La Jolla Village Drive, University California, San Diego, CA, USA. amaisel@ucsd.edu
Christian Mueller
Robert Fitzgerald
Robert Brikhan
Brian C Hiestand
Navaid Iqbal
Paul Clopton
Dirk J van Veldhuisen
University of California San Diego · USNewYork–Presbyterian Brooklyn Methodist Hospital · USUniversity Hospital of Basel · CHUniversity Medical Center Groningen · NLWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNeutrophil gelatinase-associated lipocalin (NGAL) is a measure of acute kidney injury. Renal dysfunction portends significant risk after discharge from acute heart failure (AHF). Thus, a sensitive marker of renal injury might also help to risk stratify HF patients. METHODS AND

resultsGALLANT [NGAL EvaLuation Along with B-type NaTriuretic Peptide (BNP) in acutely Decompensated Heart Failure] was a multicentre, prospective study to assess the utility of plasma NGAL, alone and in combination with BNP, as an early risk marker of adverse outcomes. We studied 186 patients (61% male). There were 29 events (AHF readmissions and all-cause mortality) at 30 days (16%). Patients with events had higher levels of NGAL than those without (134 vs. 84 ng/mL, P < 0.001). The area under the receiver operating characteristic curve was higher for NGAL (0.72) than BNP (0.65), serum creatinine (0.57), or estimated glomerular filtration rate (eGFR; 0.55). In multivariable analyses, NGAL predicted events (P= 0.001), BNP approached significance (P= 0.052 and 0.070 without creatinine and GFR, respectively) while neither serum creatinine nor eGFR were significant. The addition of discharge NGAL over BNP alone improved classification by a net 10.3% in those with events and 19.5% in those without events, for a net reclassification improvement of 29.8% (P= 0.010). Subjects with both BNP and NGAL elevated were at significant risk [hazard ratio (HR) = 16.85, P= 0.006], as were subjects with low BNP and high NGAL (HR = 9.95, P= 0.036).

conclusionsPlasma NGAL is a measure of kidney injury that at the time of discharge is a strong prognostic indicator of 30 days outcomes in patients admitted for AHF. CLINICAL TRIAL REGISTRATION NUMBER: NCT 00693745.

Indexed as

Acute DiseaseAcute Kidney InjuryAcute-Phase ProteinsAgedAged, 80 and overBiomarkersFemaleHeart FailureHumansLipocalin-2LipocalinsMaleMiddle AgedNatriuretic Peptide, BrainPilot ProjectsPredictive Value of TestsAcute-Phase ProteinsBiomarkersLCN2 protein, humanLipocalin-2LipocalinsNatriuretic Peptide, BrainProto-Oncogene Proteins

Identifiers

PMID21791540
PMCPMC3143832
OpenAlexW2102172333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.